Silverstein Russell L, Fenves Andrew Z, Ram C Venkata S
Dallas Nephrology Associates, TX, USA.
Postgrad Med. 2004 Aug;116(2):31-8, 41. doi: 10.3810/pgm.2004.08.1569.
Recognition of the role of the renin-angiotensin-aldosterone system (RAAS) in initiating and maintaining hypertension prompted the development of drugs that disrupt the RAAS, notably the angiotensin-converting enzyme (ACE) inhibitors and, more recently, the angiotensin II receptor blockers (ARBs). This article focuses on the use of ARBs in hypertension management and reviews evidence emerging from clinical trials that ARBs offer target organ protection over and above their antihypertensive activity.
